English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Primary aldosteronism (PA) is estimated to be responsible for 5-10% of all cases of hypertension (HTN)1. The current gold standard test for determining lateralisation in PA is adrenal vein sampling (AVS). 11C-Metomidate PET/CT (MTO-PET) has recently emerged as a potential non-invasive alternative to AVS2. As 11C-Metomidate is concentrated within ‘hyper-functioning’ nodules, MTO-PET potentially not only identifies the side, but the exact site of aldosterone hypersecretion, thus raising the possibility of more targeted surgical intervention.

Successful treatment of primary aldosteronism with partial adrenalectomy, facilitated by the use of 11C-Metomidate PET/CT

Successful treatment of primary aldosteronism with partial adrenalectomy, facilitated by the use of ¹¹C-Metomidate PET/CT